MarketLens

Is Bristol Myers Squibb's New Multiple Myeloma Drug a Game Changer

6 months ago

SHARE THIS ON:

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Is Bristol Myers Squibb's Deucravacitinib a Game-Changer for SLE Patients and BMY Investors

3 months ago

Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now

5 months ago

Why Are Barclays Analysts Bullish on Eli Lilly and Bristol-Myers Squibb

5 months ago

Why Are UnitedHealth Group and Bristol-Myers Squibb Attracting Hedge Funds

3 months ago

Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?

Bristol Myers' growth portfolio now accounts for 56% of revenues, led by Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion from legacy drugs.

BMY

Stock News•3 weeks ago

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

AstraZeneca and Bristol Myers Squibb are in potential merger talks to form a ~$400B pharma giant, per weekend media reports. Deal economics and patent expirations are now in focus for investors.

AZN

Stock News•1 months ago

What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment.

The race for the next standard cancer treatment is focusing on pairing two innovations, as the market looks beyond Merck's Keytruda.

MRK

Stock News•1 months ago

Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment

Bristol Myers Squibb's new drug application for mezigdomide combo therapy was accepted by the FDA for relapsed/refractory multiple myeloma, advancing toward a potential new treatment option.

BMY

Breaking News

View All →

Event-Driven Investing

Shareholder Rights

Top Headlines

View More →

Stock News•48 minutes ago

Between Amazon, Alphabet, and Meta, Microsoft is Most Likely to Deliver Best Free Cash Flow in 2026

Stock News•49 minutes ago

Amazon Web Services Backlog Reaches $496 Billion: Does That Make Amazon Stock a No Brainer Buy?

Stock News•1 hour ago

Micron (MU) Falls More Steeply Than Broader Market: What Investors Need to Know

Stock News•1 hour ago

Nvidia's $20 Billion Groq Bet Is Going Live Before the End of 2026. Here's What It Means for Investors.

Stock News•1 hour ago

Is Bristol Myers Squibb's New Multiple Myeloma Drug a Game Changer

Exclusive Content for Pro Members

Related Articles

Is Bristol Myers Squibb's Deucravacitinib a Game-Changer for SLE Patients and BMY Investors

Why is Barclays Bullish on Bristol-Myers Squibb (BMY) Now

Why Are Barclays Analysts Bullish on Eli Lilly and Bristol-Myers Squibb

Why Are UnitedHealth Group and Bristol-Myers Squibb Attracting Hedge Funds

Category

You may also like

Is BMY's Growth Portfolio Strong Enough to Offset Legacy Drug Declines?

AstraZeneca-Bristol Myers Merger Buzz Puts Patent Expiration and Deal Economics in Focus

What Comes After Merck's Keytruda? The Race for the Next Standard Cancer Treatment.

Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment

Breaking News

Featured Articles

DoorDash (DASH): Founder Selling Signals Liquidity, Not Lack of Confidence Amid Robust Growth

Sea Limited's Growth Momentum Outweighs COO's Programmed De-risking

Arista Networks' AI Momentum Encounters Founder's Planned Profit-Taking

Top Headlines

Between Amazon, Alphabet, and Meta, Microsoft is Most Likely to Deliver Best Free Cash Flow in 2026

Amazon Web Services Backlog Reaches $496 Billion: Does That Make Amazon Stock a No Brainer Buy?

Micron (MU) Falls More Steeply Than Broader Market: What Investors Need to Know

Nvidia's $20 Billion Groq Bet Is Going Live Before the End of 2026. Here's What It Means for Investors.

Q2 Earnings Season Winds Down: 3 Companies That Broke Records